SEC Form 4 · accession 0000899243-17-019200
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deval L Patrick
Director
Period of report
Jul 25, 2017
Accepted (ET)
Jul 27, 2017 · 5:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 25, 2017 | M | 12,053 | $3.40 | A | 12,053 | D | |
| Common Stock | Jul 25, 2017 | M | 15,000 | $18.85 | A | 27,053 | D | |
| Common Stock | Jul 25, 2017 | S | 27,053 | $29.69 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.40 | Jul 25, 2017 | M | 12,053 | D | — | Apr 8, 2025 | Common Stock | 12,053 | 9,375 | D |
| Employee Stock Option (right to buy)F2 | $18.85 | Jul 25, 2017 | M | 15,000 | D | — | Jun 15, 2026 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F125% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
- F2The shares vested and became exercisable in 12 equal monthly installments, with the first installment on July 16, 2016, subject to the recipient's continued service on the Issuer's Board of Directors. This option was subject to accelerated vesting upon a change of control of the Issuer.